ZAP-70 immunoreactivity is a prognostic marker of diseaseprogression in chronic lymphocytic leukemia

References

• Rozman C, Montserrat E. Chronic lymphocytic leukaemia. New England Journal of Medicine 1995; 333: 1052–1057
   PubMed Web of Science ®Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukaemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Keating M J, Chiorazzi N, Messmer B, Damle R N, Allen S L, Rai K R. Biology and treatment of chronic lymphocytic leukaemia. Hematology 2003; 153–175
   PubMedGoogle Scholar
• Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen S L. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. Journal of Clinical Investigation 1998; 102: 1515–1525
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L. IgV gene mutation status and CD 38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukaemia. Blood 2003; 101: 2049–2053
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951
   PubMed Web of Science ®Google Scholar
• Durig J, Nuckel H, Cremer M, Fhurer A, Halfmeyer K, Fandrey J. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukaemia. Leukemia 2003; 17: 2426–2434
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo N, Colomer D, Rozman M. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukaemia. New England Journal of Medicine 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Rai K R, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukaemia. New England Journal of Medicine 2003; 348: 1797–1799
   PubMed Web of Science ®Google Scholar
• Wagner S D, Cwynarski K. Chronic lymphocytic leukemia: new biological markers for assessing prognosis. The Hematology Journal 2004; 5: 197–201
   Web of Science ®Google Scholar
• Mainou-Fowler T, Dignum H M, Proctor S J, Summerfield G P. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma 2004; 45: 455–462
   PubMed Web of Science ®Google Scholar
• Orchard J A, Ibbotson R E, Davis Z, Wiestner A, Rosenwald A, Thomas P W. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111
   PubMed Web of Science ®Google Scholar
• Kim S Z, Chow K U, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer S A. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leukemia and Lymphoma 2004; 45: 2037–2045
   PubMed Web of Science ®Google Scholar
• Rassenti L, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukaemia. New England Journal of Medicine 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Baldini L, Fracchiolla N S, Cro L M, Trecca D, Romitti L, Polli E. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. Blood 1994; 84: 270–278
   PubMed Web of Science ®Google Scholar
• Mitelman F. Guidelines for cancer cytogenetics. Supplement to an international system for human cytogenetic nomenclature. Karger, Basel 1991
   Google Scholar
• Klein U, Tu Y, Stolovitzky G A, Mattioli M, Cattoretti G, Husson H. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. Journal of Experimental Medicine 2001; 194: 1625–1638
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh A A, Widhopf G, Simon R, Davis R E, Yu X. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukaemia. Journal of Experimental Medicine 2001; 194: 1639–1647
   PubMed Web of Science ®Google Scholar
• Rosenwald A. DNA microarrays in lymphoid malignancies. Oncology 2003; 17: 1743–1759
   PubMedGoogle Scholar
• Chen L, Widhopf G, Huynh L, Rassenti L, Rai K R, Weiss A. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukaemia. Blood 2002; 100: 4609–4614
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. British Journal of Haematology 1986; 62: 567–575
   PubMed Web of Science ®Google Scholar
• Admirand J H, Rassidakis G Z, Abruzzo L V, Valbuena J R, Jones D, Jeffrey Medeiros L. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Modern Pathology 2004; 17: 954–961
   PubMed Web of Science ®Google Scholar
• Sup S J, Domiati-Saad R, Kelley T W, Steinle R, Zhao X, His E D. ZAP-70 expression in B-Cell hematologic malignancy is not limited to CLL/SLL. American Journal of Clinical Pathology 2004; 122: 582–587
   PubMed Web of Science ®Google Scholar
• Lewis F, Jackson P, Lane S, Coast G, Hanby A M. Testing for HER2 in breast cancer. Histopathology 2004; 45: 207–217
   PubMed Web of Science ®Google Scholar
• Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Research 2003; 23: 3639–3650
   PubMed Web of Science ®Google Scholar